With more than a year lag between the launch of its first two startups, the venture capital- and big pharma VC-backed biotechnology incubator Cydan Development Inc. is on track to reach its goal of founding five orphan drug-focused firms in four years, including its second venture, Imara Inc.
Cydan raised $26m in 2013 from two pharma-affiliated corporate VC funds, two venture capital firms and a biotech-focused real estate...





![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
